Showing results (511-520 of 535) with videos related to

Sort By:
Pageof 54
American Journal of Hematology|February 8, 2025
Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary TherapiesJayastu Senapati, Sanam Loghavi, Jennifer Marvin-Peek, et al.
Cancer|May 6, 2026
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapyJennifer Marvin-Peek, Courtney D DiNardo, Sanam Loghavi, et al.
Cancer|August 7, 2025
Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemiaJayastu Senapati, Hagop M Kantarjian, Tapan M Kadia, et al.
JCO Precision Oncology|December 10, 2025
Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute LeukemiaHannah Goulart, Farhad Ravandi, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Patrick K Reville, Xuemei Wang, et al.
American Journal of Hematology|April 26, 2026
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Alex Bataller, Alexandre Bazinet, et al.
Blood Cancer Discovery|April 27, 2023
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid MalignanciesCurtis A Lachowiez, Sanam Loghavi, Zhihong Zeng, et al.
Genome Research|December 28, 2018
Pathogenicity and selective constraint on variation near splice sitesJenny Lord, Giuseppe Gallone, Patrick J Short, et al.
Cancer|March 19, 2021
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemiaElias Jabbour, Koji Sasaki, Nicholas J Short, et al.
Transplantation and Cellular Therapy|June 12, 2026
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDSUday R Popat, Konstantinos Lontos, Roland Bassett, et al.
Pageof 54